Loading...
•
Mar 31, 2024
Viridian Therapeutics Q1 2024 Earnings Report
Viridian Therapeutics reported first quarter 2024 financial results and highlighted recent progress.
Key Takeaways
Viridian Therapeutics reported a net loss of $48.5 million for the first quarter ended March 31, 2024. The company's cash, cash equivalents, and short-term investments were $613.2 million as of March 31, 2024, which is expected to fund operations into the second half of 2026.
THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topline readout expected in September 2024.
THRIVE-2 VRDN-001 global phase 3 clinical trial for patients with chronic TED remains on track for topline readout by year-end 2024.
Positive VRDN-003 Type C meeting held with the US Food and Drug Administration (FDA); pivotal program on track to start mid-year 2024.
VRDN-006 FcRn inhibitor remains on track for Investigational New Drug (IND) submission by year-end 2024; non-human primate data expected for VRDN-008, a half-life extended FcRn inhibitor, in the second half of 2024.
Viridian Therapeutics
Viridian Therapeutics
Viridian Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue - related party Revenue
CapyFin.com Forward Guidance
Viridian believes that its current cash, cash equivalents, and short-term investments will be sufficient to fund its operations into the second half of 2026.